sampleName	gene	mutationType	mutationExon	proteinChange	mutationFrequency	HGVS	depth	reference	mutation	chromosome	position	dbsnpID	cosmicID	drugResponse	populationFrequency	degree	duplicationTempP	uniqTempP	duplicationTempS	uniqTempS	HGVS_C	raw_ref	raw_alt	civic-gene	civic-variant	civic-variant_civic_url:civic-rating:civic-evidence_level:civic-disease:civic-drugs:civic-evidence_type:civic-evidence_direction:civic-clinical_significance:civic-variant_origin
ZK90001112FFPE1	EGFR	missense_variant	21	p.L858R	7.9%	NM_005228.3(EGFR):c.2573T>G(p.Leu858Arg)	3329	T	G	7	55259515	rs121434568	COSM6224	L858	0	uncertain	14	55	16	79	c.2573T>G	T	G	EGFR	L858R	33:0:D:Lung Adenocarcinoma:Cetuximab:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:0:C:Non-small Cell Lung Carcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation|33:0:D:Non-small Cell Lung Carcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:0:D:Lung Adenocarcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:0:D:Non-small Cell Lung Carcinoma:Neratinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:0:D:Non-small Cell Lung Carcinoma:Gefitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:0:C:Lung Adenocarcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:0:D:Hematologic Cancer:Cetuximab:Predictive:::Somatic Mutation|33:0:D:Non-small Cell Lung Carcinoma:MEDI4736:Predictive:::Somatic Mutation|33:0:D:Lung Small Cell Carcinoma:Erlotinib:Predictive:::Somatic Mutation|33:0:D:Non-small Cell Lung Carcinoma:Lapatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:0:D:Malignant Glioma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:0:D:Non-small Cell Lung Carcinoma:PF 00299804:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:0:D:Non-small Cell Lung Carcinoma:Canertinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:1:C:Lung Adenocarcinoma:Gefitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:2:B:Lung Adenocarcinoma:Gefitinib:Predictive:Does Not Support:Reduced Sensitivity:Somatic Mutation|33:2:D:Non-small Cell Lung Carcinoma:Afatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:2:C:Non-small Cell Lung Carcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:3:B:Lung Adenocarcinoma:Afatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:3:D:Cancer:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:3:D:Cancer:Gefitinib,Erlotinib,AEE788:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:3:B:Non-small Cell Lung Carcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:3:B:Lung Adenocarcinoma:Gefitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:3:B:Non-small Cell Lung Carcinoma:Gefitinib,Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:3:B:Non-small Cell Lung Carcinoma::Prognostic:Supports:Better Outcome:Somatic Mutation|33:3:B:Non-small Cell Lung Carcinoma:Gefitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:4:B:Non-small Cell Lung Carcinoma:Gefitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:4:D:Non-small Cell Lung Carcinoma:Gefitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:4:B:Lung Adenocarcinoma:Afatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:4:B:Non-small Cell Lung Carcinoma:Gefitinib,Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:5:B:Non-small Cell Lung Carcinoma:Dacomitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:5:A:Non-small Cell Lung Carcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:5:A:Non-small Cell Lung Carcinoma:Afatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
ZK90001112FFPE_test4	NTRK1	splice_donor_variant	11	NA	46.9%	NM_002529.3(NTRK1):c.1354+1G>A	5616	-	CGTT	2	29445271	NA	COSM4023454	Exon11_splice_site	0	uncertain	162	306	262	716	c.1354+1G>A	C	CCGTT	ALK	EML4-ALK T1151INST	173:2:D:Non-small Cell Lung Carcinoma:17-AAG:Predictive:Supports:Sensitivity/Response:Somatic Mutation|173:3:D:Non-small Cell Lung Carcinoma:TAE684:Predictive:Supports:Resistance:Somatic Mutation|173:3:D:Non-small Cell Lung Carcinoma:Alectinib (CH5424802):Predictive:Supports:Resistance:Somatic Mutation|173:4:C:Non-small Cell Lung Carcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation
ZK90001112FFPE_test2	NTRK1	splice_donor_variant	11	NA	46.9%	NM_002529.3(NTRK1):c.1354+1G>A	5616	TCA	-	2	48027794	NA	COSM4023454	Exon11_splice_site	0	uncertain	162	306	262	716	c.1354+1G>A	TTCA	T	MSH6	I891FS	765:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
ZK90001112FFPE3	NTRK1	splice_donor_variant	11	NA	46.9%	NM_002529.3(NTRK1):c.1354+1G>A	5616	G	A	1	156844801	NA	COSM4023454	Exon11_splice_site	0	uncertain	162	306	262	716	c.1354+1G>A	G	A	None	None	None
ZK90001112FFPE_test1	NTRK1	splice_donor_variant	11	NA	46.9%	NM_002529.3(NTRK1):c.1354+1G>A	5616	C	A	1	8073509	NA	COSM4023454	Exon11_splice_site	0	uncertain	162	306	262	716	c.1354+1G>A	C	A	ERRFI1	E384*	691:2:C:Cholangiocarcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
ZK90001112FFPE_test3	NTRK1	splice_donor_variant	11	NA	46.9%	NM_002529.3(NTRK1):c.1354+1G>A	5616	GGC	TT	3	10183794	NA	COSM4023454	Exon11_splice_site	0	uncertain	162	306	262	716	c.1354+1G>A	GGC	TT	VHL	W88fs (c.263_265delGGCinsTT)	2039:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
ZK90001112FFPE2	POLE	frameshift_variant	34	p.V1446fs	1.9%	NM_006231.3(POLE):c.4337_4338del(p.Val1446fs)	4480	CA	-	12	133220098	NA	COSM1745060	LOF	1e-04	uncertain	1	17	1	48	c.4337_4338del	CCA	C	None	None	None
